Targeted proteomics in triple negative breast cancer on FFPE samples
1.Gámez-Pozo, A. et al. Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics. PLoS ONE 12, e0178296 (2017).
- Organism: Homo sapiens
- Instrument: Orbitrap Fusion Lumos
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and usually requires the administration of adjuvant chemotherapy after surgery but even with this treatment many patients still suffer from a relapse. The main objective of this study was to identify proteomics-based biomarkers that predict the response to standard adjuvant chemotherapy, so that patients at are not going to benefit from it can be offered therapeutic alternatives.
We analyzed the proteome of a retrospective series of formalin-fixed, paraffin-embedded TNBC tissue applying high-throughput label-free quantitative proteomics. We identified several protein signatures with predictive value, which were validated with quantitative targeted proteomics (PRM) in an independent cohort of patients and further evaluated in publicly available transcriptomics data.
The targeted proteomics
cohort includes one hundred and fourteen samples from patients diagnosed of triple negative
breast cancer were retrieved from I+12 Biobank (RD09/0076/00118) and from IdiPAZ
Biobank (RD09/0076/00073), both integrated in the Spanish Hospital Biobank Network
(RetBioH; www.redbiobancos.es) between 1997 and 2012. The histopathological
features of each sample were reviewed by an experienced pathologist to confirm diagnosis
and tumor content. Eligible samples had to include at least 50% of tumor cells.
Created on 10/25/17, 9:56 AM